Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis

Clin Immunol. 2021 Jan:222:108574. doi: 10.1016/j.clim.2020.108574. Epub 2020 Aug 15.

Abstract

Eosinophilic Granulomatosis with Polyangiitis (EGPA) is an ANCA-associated small-vessels vasculitis characterized by hypereosinophilia and eosinophilic asthma. EGPA with life-threatening organ involvement, particularly cardiac and central nervous system (CNS), is a medical emergency requiring immediate immunosuppression. We describe a 58-year-old patient with a history of chronic rhinosinusitis and eosinophilic asthma, who presented with fever, hypereosinophilia and systemic inflammation. Diagnostic workup identified a cardiac mass, CNS vasculitis, CNS embolization and Staphylococcus aureus in blood cultures. Due to rapid normalization of blood cultures, the intracardiac mass was not considered as primarily infective. Active EGPA with cardiac and CNS involvement complicated by a secondary S. aureus sepsis was diagnosed. In order to not negatively impact antibacterial immunity in active EGPA, antibiotic therapy was combined with Benralizumab, which was well tolerated and EGPA resolved rapidly. Benralizumab could serve as a therapeutic option for eosinophil-mediated pathologies in severely ill patients where immunosuppressives are initially contraindicated.

Keywords: Benralizumab; Churg-Strauss vasculitis; EGPA; Eosinophilic granulomatosis with polyangiitis; Sepsis.

Publication types

  • Case Reports

MeSH terms

  • Anti-Asthmatic Agents / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Central Nervous System / pathology
  • Churg-Strauss Syndrome / drug therapy*
  • Granulomatosis with Polyangiitis / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Myocardium / pathology
  • Sepsis / drug therapy
  • Sepsis / microbiology
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / isolation & purification

Substances

  • Anti-Asthmatic Agents
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • benralizumab